FDA is considering changing its regulations to allow generic manufacturers, like brand name manufacturers, to change their labeling “in appropriate circumstances,” the Solicitor General notes in an amicus brief in Mutual Pharmaceutical Co. Inc. v. Bartlett.
Solicitor General Donald Verrilli Jr. says in a footnote that his office has been informed that FDA is considering this regulatory change
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?